ProShare Advisors LLC Acquires 36,089 Shares of OPKO Health, Inc. (NASDAQ:OPK)

ProShare Advisors LLC increased its position in OPKO Health, Inc. (NASDAQ:OPKGet Rating) by 70.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,297 shares of the biotechnology company’s stock after acquiring an additional 36,089 shares during the quarter. ProShare Advisors LLC’s holdings in OPKO Health were worth $420,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in OPK. Cornerstone Investment Partners LLC purchased a new stake in OPKO Health during the 4th quarter valued at approximately $267,000. Kestra Advisory Services LLC lifted its position in OPKO Health by 37.4% in the fourth quarter. Kestra Advisory Services LLC now owns 41,336 shares of the biotechnology company’s stock worth $199,000 after buying an additional 11,260 shares during the last quarter. Castle Rock Wealth Management LLC bought a new stake in shares of OPKO Health during the fourth quarter worth $73,000. Metropolitan Life Insurance Co NY lifted its position in shares of OPKO Health by 9.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 107,781 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 9,693 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its position in shares of OPKO Health by 24.2% during the third quarter. Rafferty Asset Management LLC now owns 870,666 shares of the biotechnology company’s stock worth $3,178,000 after purchasing an additional 169,452 shares during the last quarter. 27.83% of the stock is owned by institutional investors.

OPK opened at $3.03 on Friday. The business’s 50-day moving average is $3.22 and its two-hundred day moving average is $3.67. OPKO Health, Inc. has a 1 year low of $2.43 and a 1 year high of $5.25. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.44 and a quick ratio of 2.23. The firm has a market capitalization of $2.07 billion, a PE ratio of -16.83 and a beta of 1.88.

OPKO Health (NASDAQ:OPKGet Rating) last posted its earnings results on Monday, May 9th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). OPKO Health had a negative net margin of 7.49% and a negative return on equity of 6.86%. The company had revenue of $329.20 million during the quarter, compared to analysts’ expectations of $331.45 million. During the same quarter last year, the firm earned $0.05 EPS. OPKO Health’s revenue for the quarter was down 39.6% on a year-over-year basis. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.11 EPS for the current year.

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 750,000 shares of the company’s stock in a transaction dated Friday, February 25th. The shares were acquired at an average price of $3.09 per share, for a total transaction of $2,317,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Vice Chairman Elias A. Zerhouni purchased 89,600 shares of the company’s stock in a transaction dated Tuesday, May 10th. The shares were acquired at an average price of $2.79 per share, for a total transaction of $249,984.00. Following the purchase, the insider now directly owns 89,600 shares of the company’s stock, valued at approximately $249,984. The disclosure for this purchase can be found here. Insiders have bought 1,574,600 shares of company stock worth $4,713,884 in the last 90 days. Insiders own 41.47% of the company’s stock.

Several analysts recently weighed in on OPK shares. StockNews.com started coverage on OPKO Health in a report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research downgraded OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 price objective for the company. in a report on Monday, January 24th. Piper Sandler decreased their price objective on OPKO Health from $6.00 to $5.00 in a report on Tuesday. TheStreet downgraded OPKO Health from a “c” rating to a “d+” rating in a report on Friday, February 25th. Finally, Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Monday, January 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, OPKO Health has a consensus rating of “Hold” and an average price target of $6.00.

About OPKO Health (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Featured Articles

Institutional Ownership by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.